Ovarian Cancer | Specialty

The ovarian cancer condition center is a comprehensive resource for clinical news and expert insights on ovarian cancer. Read more at OncLive.

Five Under 5: Top Oncology Videos for the Week of 2/23

March 2nd 2025

The top 5 videos of the week cover insights in ovarian cancer, NSCLC, CSCC, follicular lymphoma, and CLL.

Dr Lheureux on Advancements in Targeted Treatment Delivery for Ovarian Cancer

February 25th 2025

Stéphanie Lheureux, MD, PhD, discusses technological advancements in ovarian cancer that could optimize treatment delivery, timing, and sequencing.

Avutometinib/Defactinib Combo Could Fill Sizeable Unmet Need in LGSOC

February 17th 2025

Ritu Salani, MD, MBA, details the significance of trials examining avutometinib plus defactinib and enthusiasm for ADCs in ovarian cancer.

FDA Grants Fast Track Designation to CUSP06 for Platinum-Resistant Ovarian Cancer

February 12th 2025

CUSP06 received fast track designation from the FDA for patients with platinum-resistant ovarian cancer.

Precise Targets and Drug Sequencing Potential Characterize the State of ADCs in Ovarian Cancer

February 11th 2025

Kathleen N. Moore, MD, MS, discusses ongoing trials of novel ADCs in ovarian cancer and the potential relevance of biomarker expression for these agents.

Dr Moore on the 2024 FDA Approval of Mirvetuximab Soravtansine in Ovarian Cancer

February 10th 2025

Kathleen N. Moore, MD, MS, details the March 2024 approval of mirvetuximab soravtansine for the treatment of FRα–positive ovarian cancer.

Ongoing Research to Watch in Ovarian Cancer

February 6th 2025

Floortje J. Backes, MD, discusses ongoing research to watch in ovarian cancer.

Additional Potential Roles for Mirvatuximab Soravtansine and Other ADCs in Ovarian Cancer

February 6th 2025

Floortje J. Backes, MD, discusses other potential roles for mirvatuximab soravtansine and other antibody-drug conjugates in ovarian cancer.

PICCOLO Data for Mirvatuximab Soravtansine in FRα+, Platinum-Sensitive Ovarian Cancer

February 6th 2025

Floortje J. Backes, MD, discusses data for mirvatuximab soravtansine in FRα-positive, platinum-sensitive ovarian cancer

Testing for FRα in Ovarian Cancer

February 6th 2025

Floortje J. Backes, MD, discusses how to approach FRα testing in ovarian cancer.

How Mirvatuximab Soravtansine Has Impacted Clinical Management of Ovarian Cancer

February 6th 2025

Floortje J Backes, MD, discusses how mirvatuximab soravtansine has affected the management of platinum-resistant ovarian cancer.

Current Treatment Considerations for Platinum-Resistant Ovarian Cancer

February 6th 2025

Floortje J Backes, MD, discusses current treatment considerations for platinum-resistant ovarian cancer.

Gemogenovatucel-T Receives FDA RMAT Designation for Advanced HRP Ovarian Cancer

February 5th 2025

The FDA granted RMAT designation to gemogenovatucel-T for maintenance treatment after frontline chemotherapy in advanced HRP ovarian cancer.

Dr Moore on the Relationship Between Biomarker Expression and Efficacy With ADCs in Ovarian Cancer

February 1st 2025

Kathleen N. Moore, MD, MS, discusses the relationship between biomarker expression and efficacy with antibody-drug conjugates in ovarian cancer.

ADC Development in Ovarian Cancer: What's Next for FRa and Beyond?

January 31st 2025

Kathleen Moore, MD, MD, FASCO, discusses the development of antibody-drug conjugates in ovarian cancer and how they could shift the field.

Dr Naumann on Next-Generation Antibody-Drug Conjugates in Ovarian Cancer

January 31st 2025

R. Wendel Naumann, MD, discusses next-generation antibody-drug conjugates in ovarian cancer.

Dr Lheureux on the Evolution of ADCs Since Mirvetuximab Soravtansine in Ovarian Cancer

January 31st 2025

Stéphanie Lheureux, MD, PhD, discusses the evolution of antibody-drug conjugates since mirvetuximab soravtansine in ovarian cancer.

Trend Towards Favorable DFS Observed With Cisplatin/Paclitaxel in HRD Advanced Ovarian Cancer

January 31st 2025

Cisplatin/paclitaxel showed trend towards improved DFS vs cisplatin alone in advanced-stage ovarian cancer.

ADC Anetumab Ravtansine Does Not Improve PFS vs Paclitaxel in High-Grade Serous Ovarian Cancer

January 30th 2025

Anetumab ravtansine plus bevacizumab failed to improve efficacy vs paclitaxel plus bevacizumab in platinum-resistant high-grade ovarian cancer.

Olaparib Elicits Improved OS Rates in Platinum-Sensitive, Germline/Somatic BRCA+ Relapsed Ovarian Cancer

January 29th 2025

A final analysis of the LIGHT trial showed olaparib demonstrated higher OS rates in patients with relapsed ovarian cancer who had germline or somatic BRCA mutations.